Emyria Expands Into NSW With 4-Bed Psychedelics Clinic Targeting 2.5M Catchment
Emyria has executed a term sheet with Matilda Healthcare to establish a dedicated Empax clinic at Matilda Nepean Private Hospital in Kingswood, New South Wales. The partnership marks the company’s entry into Australia’s most populous state and represents the third independent private hospital operator to join Emyria’s national clinic network. Clinic commencement is targeted for Q3 CY2026, subject to regulatory approvals.
The new site will establish four treatment beds, expanding total national capacity to 18 beds across five locations. Positioned in Western Sydney, the Kingswood facility serves a catchment of more than 2.5 million people and provides access to patients across regional North West New South Wales, including Dubbo, Orange, Bathurst, Tamworth, and Mudgee.
What is psychedelic-assisted therapy and why does scale matter?
Psychedelic-assisted therapy refers to the use of controlled psychedelic substances, such as MDMA or psilocybin, in combination with structured psychotherapy to treat conditions like post-traumatic stress disorder (PTSD) and treatment-resistant depression. Unlike conventional psychiatric medications, these treatments require specialised clinical infrastructure, licensed hospital facilities with Schedule 8 drug approvals, and psychiatrists approved as Authorised Prescribers by the Therapeutic Goods Administration.
National scale matters because it enables real-world data collection across diverse patient populations, supports clinical trial infrastructure for drug development sponsors, and demonstrates regulatory and clinical credibility. Companies with established multi-state networks are better positioned to capture market share as psychedelic-assisted therapies gain wider acceptance and move toward broader regulatory approvals.
For Emyria, a national footprint strengthens its value proposition to international pharmaceutical sponsors seeking Australian clinical trial sites and real-world evidence generation. Scale becomes a competitive moat in an emerging sector where infrastructure, regulatory relationships, and clinical governance separate leaders from entrants.
When big ASX news breaks, our subscribers know first
National clinic footprint now spans four states
Emyria’s Empax network now operates or is establishing clinics across Western Australia, Queensland, Victoria, and New South Wales, creating a presence in every major East and West Coast state. The partnership with Matilda Healthcare, a third independent hospital operator, demonstrates growing industry acceptance of Emyria’s clinical governance model.
| Site | Jurisdiction | Status | Notes |
|---|---|---|---|
| Perth (x2 centres) | Western Australia | Operating | Existing capacity |
| Brisbane (Avive) | Queensland | Operating | Existing capacity |
| Mornington Peninsula | Victoria | Operational Q2 CY26 | Existing capacity |
| Matilda Healthcare, Kingswood | New South Wales | Term sheet executed | **4 new beds** |
The geographic distribution positions Emyria to serve patients in Australia’s four most populous states, broadening its addressable market materially. Clinical workforce recruitment in New South Wales is already underway to support operationalisation ahead of the targeted Q3 CY2026 launch.
Authorised Prescriber network doubles to 12
Emyria has received six new Authorised Prescriber approvals from the Therapeutic Goods Administration, doubling its psychiatrist cohort from 6 to 12. The newly approved psychiatrists will support the Perth, Brisbane, and Mornington Peninsula clinics.
A further eight psychiatrists are due to attend New South Wales Empax training in June to support their Authorised Prescriber applications. The growing AP cohort provides evidence of psychiatrist acceptance of Emyria’s clinical governance, infrastructure, and treatment protocols.
Authorised Prescriber growth is a leading indicator of treatment capacity. Under Australia’s regulatory framework, psychedelic-assisted therapies can only be administered by psychiatrists who hold individual Authorised Prescriber approvals for specific substances. More approved psychiatrists translate directly to higher patient throughput and revenue potential.
Partnership strengthens Empax Global Partnership Program
The New South Wales expansion broadens geographic reach for the Empax Global Partnership Program, announced by Emyria on 20 April 2026. The programme positions Emyria’s national clinic network as clinical infrastructure for international drug development sponsors seeking Australian trial sites and real-world evidence generation.
The five-site network provides dual revenue opportunities: direct patient treatment fees under the Authorised Prescriber pathway and potential partnership income from pharmaceutical sponsors conducting clinical trials or seeking post-market surveillance data. National scale enhances Emyria’s value proposition to sponsors requiring multi-site trial capacity or geographically diverse patient cohorts.
Key partnership terms
The Matilda Healthcare agreement includes the following commercial provisions:
- Initial term: 3 years, with two further renewal options (subject to Emyria satisfying a minimum utilisation condition)
- Licence fee: Payable monthly, with increased rates in year 2
- Exclusivity: Exclusive rights for psychedelic-assisted therapy at the facility; first right of refusal for other Matilda sites
- Operations: Empax provides clinical team and care model; Matilda provides licensed hospital space, Schedule 8 licensure, secure storage/drug management
- Binding terms: Key commercial, confidentiality, exclusivity, and financial provisions are binding; formal licence agreement to follow
The agreement remains subject to execution of a formal licence agreement.
The next major ASX story will hit our subscribers first
Executive Chair outlines national ambition
Greg Hutchinson, Executive Chair
“Establishing an Empax clinic in New South Wales provides Emyria a presence in every major Australian State and Territory, and increases treatment room capacity to 18. Matilda Healthcare was selected for its strategic reach into Western Sydney and the underserved North West New South Wales region. Combined with the launch of the Empax Global Partnership Program and recent Authorised Prescriber approvals, this further expansion provides Emyria the national scale and clinical workforce to help deliver on our ambition to be the leading platform for advanced mental health therapies in Australia, and as a global partner for international drug development sponsors.”
The New South Wales clinic represents a geographic milestone that positions Emyria with national infrastructure across Australia’s largest states by population, supporting both direct patient care and clinical trial partnership revenue streams.
Want to Follow Emyria’s National Clinic Expansion?
Emyria’s partnership with Matilda Healthcare extends its psychedelic-assisted therapy network into New South Wales, targeting Australia’s largest state market with four new treatment beds. The five-site national footprint now positions the company to serve over 2.5 million people in Western Sydney alone while supporting pharmaceutical partnerships through the Empax Global Partnership Program.
To track Emyria’s progress as it scales treatment capacity and builds clinical trial infrastructure, visit the Emyria investor centre for company updates, regulatory milestones, and partnership announcements.